Diabetes Medicine Franchise in Ahmedabad

Anti-diabetic Tablet Supplier in Mumbai

Type 2 Diabetes Medicine Distributor in Delhi

Oral Hypoglycemic Tablet Manufacturer in Bangalore

Diabetes Care Tablet Stockist in Hyderabad
Diabetology Medicine Exporter in Chandigarh

Home/Products /sitagliptin-50mg-glimepiride-2mg-metformin-1000mg-sr-tablet

Istalab GM 2-1000 Tablet

Composition : Sitagliptin (50mg) + Glimepiride (2mg) + Metformin (1000mg) SR Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹1/-

Sitagliptin 50mg + Glimepiride 2mg + Metformin 1000mg SR Tablet is a fixed-dose triple combination indicated for the treatment of type 2 diabetes mellitus in patients who require enhanced and sustained blood glucose control.

This formulation works through multiple complementary mechanisms—sitagliptin improves incretin activity and insulin release, glimepiride stimulates pancreatic insulin secretion, and metformin reduces hepatic glucose production while improving peripheral insulin sensitivity.

Clinically, it is prescribed for patients with poor glycemic control on dual therapy, helping regulate both fasting and postprandial blood glucose levels and lowering the risk of diabetes-related complications.

With increasing demand for high-strength, comprehensive diabetes therapies, this combination strengthens treatment portfolios, supports consistent prescriptions, and helps expand reach among physicians managing complex diabetic cases.

Read More

About the Product

Sitagliptin 50mg + Glimepiride 2mg + Metformin 1000mg SR Tablet is a fixed-dose triple combination indicated for the treatment of type 2 diabetes mellitus in patients who require enhanced and sustained blood glucose control.

This formulation works through multiple complementary mechanisms—sitagliptin improves incretin activity and insulin release, glimepiride stimulates pancreatic insulin secretion, and metformin reduces hepatic glucose production while improving peripheral insulin sensitivity.

Clinically, it is prescribed for patients with poor glycemic control on dual therapy, helping regulate both fasting and postprandial blood glucose levels and lowering the risk of diabetes-related complications.

With increasing demand for high-strength, comprehensive diabetes therapies, this combination strengthens treatment portfolios, supports consistent prescriptions, and helps expand reach among physicians managing complex diabetic cases.

Common side effects may include nausea, diarrhea, abdominal discomfort, dizziness, or headache. Hypoglycemia may occur, especially when combined with other antidiabetic agents. Rarely, lactic acidosis or allergic reactions may occur.

Istalab GM 2/1000 Tablet is indicated for the management of type 2 diabetes mellitus in patients whose blood glucose levels are not adequately controlled with diet and exercise alone. It helps in achieving better fasting and postprandial blood glucose control as advised by a physician.

Use this medicine strictly under medical supervision. Follow the prescribed dosage and timing. Regular monitoring of blood glucose is essential. Caution is advised in patients with renal impairment, hepatic disorders, or elderly patients.

Store below 25°C in a cool, dry place. Protect from moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation